Role of Erlotinib in First-line and Maintenance Treatment of Advanced Non-small-cell Lung Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2010 Dec 29

PMID 21188105

Citations 13

Authors

Noemi Reguart

Andres Felipe Cardona

Rafael Rosell

Affiliations

Soon will be listed here.

Abstract

Erlotinib hydrochloride (Tarceva(®)) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as "targeted therapies" designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients' outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents.

Citing Articles

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.

Wang Y, Wu G, Li R, Luo Y, Huang X, He L Front Public Health. 2021; 9:677862.

PMID: 34222178 PMC: 8249768. DOI: 10.3389/fpubh.2021.677862.

Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.

Sanachai K, Aiebchun T, Mahalapbutr P, Seetaha S, Tabtimmai L, Maitarad P RSC Med Chem. 2021; 12(3):430-438.

PMID: 34046625 PMC: 8130606. DOI: 10.1039/d0md00436g.

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?.

Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S Cancer Biol Ther. 2015; 16(8):1148-59.

PMID: 26061272 PMC: 4623405. DOI: 10.1080/15384047.2015.1056415.

Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.

Xu R, Wang Q J Biomed Inform. 2015; 55:64-72.

PMID: 25817969 PMC: 4582661. DOI: 10.1016/j.jbi.2015.03.009.

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy.

Zhuang H, Hou H, Yuan Z, Wang J, Pang Q, Zhao L Onco Targets Ther. 2014; 7:807-13.

PMID: 24920921 PMC: 4043804. DOI: 10.2147/OTT.S62707.

References

Smith I, OBrien M, Talbot D, Nicolson M, Mansi J, Hickish T . Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19(5):1336-43. DOI: 10.1200/JCO.2001.19.5.1336. View

Park J, Kim S, Ahn J, Suh C, Lee J, Jang J . Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33):5233-9. DOI: 10.1200/JCO.2007.10.8134. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

OReilly K, Rojo F, She Q, Solit D, Mills G, Smith D . mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3):1500-8. PMC: 3193604. DOI: 10.1158/0008-5472.CAN-05-2925. View

Mitsudomi T, Kosaka T, Yatabe Y . Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006; 11(3):190-8. DOI: 10.1007/s10147-006-0583-4. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

10.

Soon Y, Stockler M, Askie L, Boyer M . Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27(20):3277-83. DOI: 10.1200/JCO.2008.19.4522. View

11.

Vincent M . Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol. 2009; 16(4):9-21. PMC: 2722061. DOI: 10.3747/co.v16i4.465. View

12.

Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13):3908-14. DOI: 10.1158/1078-0432.CCR-06-0462. View

13.

Jiang J, Greulich H, Janne P, Sellers W, Meyerson M, Griffin J . Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005; 65(19):8968-74. DOI: 10.1158/0008-5472.CAN-05-1829. View

14.

Wong K, Fracasso P, Bukowski R, Lynch T, Munster P, Shapiro G . A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009; 15(7):2552-8. DOI: 10.1158/1078-0432.CCR-08-1978. View

15.

Hammerman P, Janne P, Johnson B . Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009; 15(24):7502-7509. DOI: 10.1158/1078-0432.CCR-09-0189. View

16.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

17.

Goldie J, Coldman A, Gudauskas G . Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982; 66(3):439-49. View

18.

Jalal S, Ademuyiwa F, Hanna N . The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2009; 21(2):110-5. DOI: 10.1097/CCO.0b013e328322cf49. View

19.

Mok T . Living with imperfection. J Clin Oncol. 2009; 28(2):191-2. DOI: 10.1200/JCO.2009.25.8574. View

20.

Jackman D, Miller V, Cioffredi L, Yeap B, Janne P, Riely G . Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16):5267-73. PMC: 3219530. DOI: 10.1158/1078-0432.CCR-09-0888. View